Extracorporeal Photopheresis (ECP)

DEVICE11 trials

Sponsors

Washington University School of Medicine, University of Aarhus, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Therakos, Inc., a Mallinckrodt Company

Conditions

Atopic DermatitisBronchiolitis Obliterans Syndrome (BOS)Chronic Graft vs. Host DiseaseChronic Graft-versus-host-diseaseDiffuse Cutaneous Systemic SclerosisGraft Versus Host DiseaseGraft vs Host DiseaseGraft-Versus-Host Disease

Early Phase 1

Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study)

Not yet recruitingNCT06703333

Yandy Marx Castillo AlemanStiff Person Syndrome

Start: 2026-01-31End: 2027-07-31Target: 3Updated: 2025-10-06

Phase 2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

TerminatedNCT02322190

National Cancer Institute (NCI)Chronic Graft vs. Host Disease, Graft-Versus-Host Disease, Graft vs Host Disease

Start: 2014-12-20End: 2019-10-31Updated: 2020-03-12

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

CompletedNCT02340676

Dana-Farber Cancer InstituteChronic Graft-versus-host-disease

Start: 2015-02-01End: 2025-09-01Updated: 2026-02-20

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

TerminatedNCT04446182

University of UtahChronic Graft-versus-host-disease

Start: 2021-01-29End: 2023-01-30Updated: 2024-01-22

Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Not yet recruitingNCT04986605

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sDiffuse Cutaneous Systemic Sclerosis

Start: 2025-07-01End: 2027-07-31Target: 15Updated: 2025-03-13

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

WithdrawnNCT05333029

Molly GalloglyGraft Versus Host Disease

Start: 2024-10-01End: 2025-06-01Updated: 2025-01-07

Phase 3

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

Active, not recruitingNCT02181257

Washington University School of MedicineBronchiolitis Obliterans Syndrome (BOS)

Start: 2015-01-31End: 2028-12-31Updated: 2025-04-17

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

TerminatedNCT02524847

Therakos, Inc., a Mallinckrodt CompanySteroid Refractory Acute Graft Versus Host Disease

Start: 2016-01-20End: 2019-07-16Updated: 2020-09-11

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

CompletedNCT03112603

Incyte CorporationGraft-versus-host Disease (GVHD)

Start: 2017-06-29End: 2022-12-15Updated: 2025-08-12

Unknown Phase

Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis

CompletedNCT02226068

University of AarhusAtopic Dermatitis

Start: 2002-06-30End: 2004-01-31Updated: 2015-03-27

Extracorporeal Photopheresis in Sezary Syndrome

RecruitingNCT05157581

Oleg E. Akilov, MD, PhDSezary Syndrome

Start: 2023-04-04End: 2028-12-31Target: 20Updated: 2025-12-30

Related Papers

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

Journal of Clinical Oncology2025-06-251 citations

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

Blood Advances2025-06-05

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Blood2023-11-025 citations

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Blood2022-11-15

P1389: RUXOLITINIB DEMONSTRATES A GREATER CORTICOSTEROID-SPARING EFFECT THAN BEST AVAILABLE THERAPY IN PATIENTS WITH CORTICOSTEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE

HemaSphere2022-06-01

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy

The Oncologist2022-02-0927 citations

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Blood2021-11-051 citations

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

New England Journal of Medicine2021-07-14453 citations

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis

Frontiers in Immunology2021-02-1520 citations

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Blood2020-11-0537 citations

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Blood2020-11-04

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

New England Journal of Medicine2020-04-22813 citations

Ruxolitinib for the treatment of graft-versus-host disease.

2020-04-0119 citations

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Blood2019-11-132 citations

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos® Cellex® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

Blood2019-11-13

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease

Blood Advances2019-04-0139 citations

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BMC Cancer2018-11-1954 citations

Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3)

Biology of Blood and Marrow Transplantation2018-02-03

Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials

Immunotherapy2018-01-1093 citations